Fabrication of hyaluronic acid-based micelles with glutathione-responsiveness for targeted anticancer drug delivery

[Display omitted] Hyaluronic acid (HA), a natural polymer, has gained much attention recently because of its good biocompatibility and extensive availability. Herein, a novel drug delivery system based on hyaluronic acid-tetraphenyl ethylene conjugate (HA-SS-TPE) with glutathione (GSH)-responsivenes...

Full description

Saved in:
Bibliographic Details
Published inJournal of colloid and interface science Vol. 606; no. Pt 2; pp. 1586 - 1596
Main Authors Yan, Ke, Feng, Yecheng, Gao, Ke, Shi, Xiaojing, Zhao, Xubo
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 15.01.2022
Subjects
Antineoplastic Agents - pharmacology
Cancer therapy
Doxorubicin - pharmacology
Drug delivery system
Drug Delivery Systems
Drug Liberation
Glutathione - metabolism
GSH-responsiveness
HeLa Cells
Humans
Hyaluronic Acid
Hydrogen-Ion Concentration
Micelles
Self-assembly
GSH-responsiveness
Self-assembly
Hyaluronic acid
Drug delivery system
Cancer therapy
Online AccessGet full text

Cover

More Information
Summary:[Display omitted] Hyaluronic acid (HA), a natural polymer, has gained much attention recently because of its good biocompatibility and extensive availability. Herein, a novel drug delivery system based on hyaluronic acid-tetraphenyl ethylene conjugate (HA-SS-TPE) with glutathione (GSH)-responsiveness for targeted drug delivery is designed. During the self-assembly of HA-SS-TPE, doxorubicin (DOX) is loaded to form DOX-loaded polymeric micelles. These as-prepared DOX-loaded polymeric micelles not only exhibit fluorescent emission, but also fast glutathione-triggered dissociation to unload DOX by responding to tumor microenvironments. In-vitro investigations showed that the DOX-loaded polymeric micelles presented a higher intracellular release ratio in CD44-positive cells (ES2 and Hela) than in CD44-negative cells (MCF-7 and L929). Notably, in vivo investigations showed that DOX@HA-SS-TPE significantly suppressed tumor growth. As a result, such a GSH-responsive drug delivery system with fluorescent feature provides a potential treatment for CD44-overexpressing cancers.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0021-9797
1095-7103
DOI:10.1016/j.jcis.2021.08.129